论文部分内容阅读
目的:探讨AngⅡ及AT1R在子宫内膜腺癌中的表达及其临床意义。方法:采用免疫组织化学SP法检测50例子宫内膜腺癌,15例子宫内膜非典型增生及10例正常子宫内膜组织中AngⅡ及AT1R蛋白的表达。结果:AngⅡ及AT1R主要定位在细胞浆及胞膜中,大都呈弥漫性表达,在正常子宫内膜,非典型增生内膜及子宫内膜腺癌的阳性表达率分别是10%/20%,47%/33%,86%/72%。AngⅡ及AT1R在子宫内膜腺癌的表达显著高于非典型增生及正常子宫内膜组(P<0.05),AngⅡ及AT1R在非典型增生内膜组及正常子宫内膜组的表达无显著差异(P>0.05);AngⅡ在各期子宫内膜腺癌组织的表达无显著差异(P>0.05),AT1R在Ⅰ、Ⅱ期子宫内膜腺癌组织的表达显著高于Ⅲ期子宫内膜腺癌组织(P<0.05);AngⅡ及AT1R在子宫内膜腺癌侵及肌层深层组及浅层组,有淋巴结转移组和无淋巴结转移组的表达均无显著差异(P>0.05)。结论:AngⅡ及AT1R可能参与了子宫内膜腺癌的发生和发展,选择性拮抗AT1受体可能为子宫内膜腺癌的预防及治疗提供新的靶点。
Objective: To investigate the expression of Ang Ⅱ and AT1R in endometrial adenocarcinoma and its clinical significance. Methods: Immunohistochemical SP method was used to detect the expression of Ang Ⅱ and AT1R protein in 50 cases of endometrial adenocarcinoma, 15 cases of endometrial dysplasia and 10 cases of normal endometrium. Results: Ang Ⅱ and AT1R were mainly localized in the cytoplasm and membrane, most of which were diffusely expressed. The positive rates of AngⅡ and AT1R were 10% / 20% in normal endometrium, atypical endometriosis and endometrial adenocarcinoma respectively. 47% / 33%, 86% / 72%. The expressions of AngⅡ and AT1R in endometrial adenocarcinoma were significantly higher than those in atypical hyperplasia and normal endometrium (P <0.05). The expressions of AngⅡ and AT1R in atypical hyperplasia endometrium and normal endometrium were not significantly different (P> 0.05). The expression of AngⅡin endometrial adenocarcinoma had no significant difference (P> 0.05). The expression of AT1R in stageⅠ, Ⅱ endometrial adenocarcinoma was significantly higher than that in stage Ⅲ endometrial adenocarcinoma (P <0.05). There was no significant difference in the expression of Ang Ⅱ and AT1R between the deep and the superficial group with invasion of endometrial adenocarcinoma and lymph node metastasis (P> 0.05). CONCLUSION: AngⅡ and AT1R may be involved in the occurrence and development of endometrial adenocarcinoma. Selective antagonism of AT1 receptor may provide a new target for the prevention and treatment of endometrial adenocarcinoma.